Is semaglutide a target therapy for acquired hypothalamic obesity?
- PMID: 39212830
- DOI: 10.1007/s11102-024-01443-7
Is semaglutide a target therapy for acquired hypothalamic obesity?
Keywords: Craniopharyngioma; GLP-1, treatment; Hypothalamus; Obesity.
References
-
- Busetto L, Dicker D, Frühbeck G, Halford JCG, Sbraccia P, Yumuk V, Goossens GH (2024) A new framework for the diagnosis, staging and management of obesity in adults. Nat Med. https://doi.org/10.1038/s41591-024-03095-3 - DOI - PubMed
-
- Gruber T, Lechner F, Krieger JP, García-Cáceres C (2024) Neuroendocrine gut-brain signaling in obesity. Trends Endocrinol Metab. https://doi.org/10.1016/j.tem.2024.05.002 - DOI - PubMed
-
- Garvey WT (2022) New Horizons. A new paradigm for treating to target with second-generation obesity medications. J Clin Endocrinol Metab. https://doi.org/10.1210/clinem/dgab848 - DOI - PubMed
-
- Gan HW, Cerbone M, Dattani MT (2024) Appetite- and weight-regulating neuroendocrine circuitry in hypothalamic obesity. Endocr Rev. https://doi.org/10.1210/endrev/bnad033 - DOI - PubMed
-
- Lister NB, Baur LA, Felix JF, Hill AJ, Marcus C, Reinehr T, Summerbell C, Wabitsch M (2023) Child and adolescent obesity. Nat Rev Dis Primers. https://doi.org/10.1038/s41572-023-00435-4 - DOI - PubMed
Publication types
LinkOut - more resources
Full Text Sources